Intervention not reported
- Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
LCPUFA supplemented formula showed no clear difference in visual acuity/Teller cards at 12 months (cycles/degree) ‐ DHA and AA… compared with control formula (low certainty).
LCPUFA supplemented formula showed no clear difference in sweep VEP acuity at 12 months (LogMAR) ‐ DHA and AA vs normal term… compared with control formula (low certainty).
LCPUFA supplemented formula showed no clear difference in MDI scores (Bayley) at 18 months ‐ DHA and AA vs normal term formula compared with control formula (low certainty).
LCPUFA supplemented formula showed no clear difference in PDI scores (Bayley) at 18 months ‐ DHA and AA vs normal term formula compared with control formula (low certainty).
LCPUFA supplemented formula showed no clear difference in weight at 12 months (z scores) ‐ DHA and AA vs normal term formula compared with control formula (low certainty).
LCPUFA supplemented formula showed no clear difference in length at 12 months (z scores) ‐ DHA and AA vs normal term formula compared with control formula (low certainty).
LCPUFA supplemented formula showed no clear difference in head circumference at 12 months (z scores) ‐ DHA and AA vs normal… compared with control formula (low certainty).
The intervention showed no clear difference in bayley MDI at 12 months post‐term (low certainty).
The intervention showed no clear difference in bayley PDI at 12 months post‐term (low certainty).
The intervention showed no clear difference in weight at 12 months post‐term (kg) (low certainty).
The intervention showed no clear difference in length at 12 months post‐term (cm) (low certainty).
The intervention showed no clear difference in head circumference at 12 months post‐term (cm) (low certainty).
It is very uncertain whether higher changes all allergic disease ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes all allergic disease ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes asthma ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes allergic rhinitis ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ childhood prevalence compared with lower PUFA intake (very low certainty).